ImmunoGen, Inc. (IMGN - Free Report) announced positive interim results from an ongoing phase I study (n=34) of SAR566658. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
SAR566658 is being developed for the treatment of ovarian, breast, and other epithelial cancer forms. Data from the study revealed that SAR566658 was generally well tolerated. Moreover, the data showed that SAR566658 was capable of inducing objective responses and sustained stable disease in heavily pre-treated patients suffering from CA6-positive cancer.
ImmunoGen mentioned in its press release that limited adverse events normally associated with cytotoxic chemotherapy was observed during the study. The candidate was evaluated at doses bet 10-240 mg/m2 in this portion of the study for 3 weeks. The recommended dosage was identified as 190. SAR566658 is now being assessed at the recommended dose in the extension phase of the study.
ImmunoGen has an agreement with Sanofi (SNY - Free Report) for the development of SAR566658, and the initiation of clinical testing. SAR566658 has been developed using ImmunoGen’s Targeted Antibody Payload (TAP) technology. Two more compounds, SAR3419 and SAR650984, developed through the TAP technology, are currently in clinical trials, also in collaboration with Sanofi.
SAR3419 is currently in a phase II study being developed for the treatment of non-Hodgkin lymphoma. Meanwhile, SAR650984 is currently being developed in a phase I study for the treatment of blood cancer including multiple myeloma.
We are encouraged by ImmunoGen’s association with companies of the likes Sanofi and Eli Lilly and Company (LLY - Free Report) . The company is expected to ink more deals in the future for further pipeline development.
ImmunoGen presently carries a Zacks Rank #3 (Hold). Meanwhile, stocks such as Actelion Ltd. look better positioned with a Zacks Rank #1 (Strong Buy).